arrow
M

María Trojano

University of Bari Aldo Moro
H指数:92
被引数:3.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Validation of generative artificial intelligence techniques for synthetic data generation in multiple sclerosis research: A comparison with real-world evidence from the Italian multiple sclerosis registry

生成式人工智能技术在多发性硬化症研究中合成数据生成中的验证:与意大利多发性硬化症登记处真实世界证据的比较

2026-10-140
PRE
Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study)

评估接受不同治疗方案序列治疗的视神经脊髓炎患者队列中长期严重不良事件风险的概况:意大利视神经脊髓炎及相关疾病登记研究(I-MS&RD)(ProSA研究)结果

2026-07-040
PRE
Reduced Childhood Outdoor Exposure Raises Pediatric Multiple Sclerosis (PedMS) Risk

儿童户外暴露减少会增加儿科多发性硬化(PedMS)的风险

2026-05-240
OAAI
Correction: Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study

更正:臭氧污染作为年轻人多发性硬化的可能诱因:PEDIGREE研究

2026-05-180
PRE
A narrative review of genetic and environmental factors and risk for multiple sclerosis. The design of the Italian multicentric PEDIGREE study

关于遗传和环境因素与多发性硬化风险的叙事性综述。意大利多中心PEDIGREE研究的设计

2025-08-150
PRE
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network

原发性进行性MS患者亚类的疾病改善治疗和残疾进展: 来自大MS数据网络的结果

2024-12-060
OAAI
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

那他珠单抗和ocrelizumab对多发性硬化疾病进展的比较

2024-07-053
OA
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

那他珠单抗治疗继发性进行性多发性硬化的长期疗效: 一项倾向匹配研究

2024-07-011
OAAI
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

控制小儿多发性硬化症患者残疾恶化的疾病改善疗法: 全球和国家注册机构的纵向分析

2024-05-014
PRE
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
2023-10-019
OAAI
Sars-CoV2 infection in pregnant women with multiple sclerosis

多发性硬化症孕妇的Sars-CoV2感染

2023-05-261
OA
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

活动性继发性进行性多发性硬化症患者的造血干细胞移植

2023-03-1415
OA
Secondary Progressive Multiple Sclerosis A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies

继发性进行性多发性硬化临床特征,定义,预后工具和疾病改善疗法的回顾

2023-01-0126
OAAI
Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
2022-12-313
OAAI
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

继发性进行性MS患者长期残疾轨迹的异质性: 来自大MS数据网络的潜在类别分析

2022-09-2812
PRE